Table 4 Unweighted and propensity-score weighted analysis of safety outcomes
Adverse drug event | Combinationa (n = 95) | Monotherapya (n = 118) | Propensity score-weighted regression OR (95% CI) |
|---|---|---|---|
Acute kidney injury | 28/71 (39) | 38/104 (37) | 1.49 (0.60, 3.34) |
 KDIGO Stage 1 | 15/71 (21) |  25/104 (24) | -- |
 KDIGO Stage 2 | 7/71 (10) | 10/104 (10) | -- |
 KDIGO Stage 3 | 6/71 (8) | 4/104 (4) | 2.69 (0.60, 12.13) |
Neutropenia | 6/78 (8) | 9/89 (9) | 1.21 (0.37, 3.98) |
Eosinophilia | 20/78 (26) | 20/90 (22) | 1.45 (0.66, 3.19) |
Elevated CPK | 3/53 (6) | 3/31 (10) | -- |
Rash | 1/90 (1) | 2/105 (2) | -- |
ADE leading to antibiotic change or discontinuation | 9/95 (9) | 9/118 (8) | 1.10 (0.36, 3.32) |